Finally, @Merck publishes its rationale for pursuing certain solid tumors besides #melanoma & #lungcancer with earlier Keytruda monotherapy trials. It was based on molecular profiling of ~16000 primary/met cancers looking at PD-L1, immune signatures.https://t.co/iPhHEKAPv4 pic.twitter.com/sRBUVBmpOb
— Anirban Maitra (@Aiims1742) January 12, 2019
Is this Editas paper today the first peer-reviewed publication of monkey data from a CRISPR company? https://t.co/UN2XzqjEm2 $EDIT
— Emily Mullin (@emilylmullin) January 21, 2019
I missed this #openaccess CAR-T review by M. Maus & colleagues (online on 31/12 !) but it sums it up very well and not in 20 pages. Also great insights on the constructs & the properties.
— Biotech Radar (@BiotechRadar) January 24, 2019
Engineering and Design of Chimeric Antigen Receptorshttps://t.co/cEjDkyvcxA
more reminders that we don't know beans about Tshttps://t.co/5TotrZUVJjhttps://t.co/EFh157F48s
— Paul D. Rennert (@PDRennert) January 24, 2019
ps. and we thought we understood PD-1
pps. now go ahead and tell me all about yer important Tregs, I dare ya
Probably the best written and most-accessible article I have ever read about p-values, confidence intervals, power and their misconceptions. Simply a MUST READ for any scientist! Thank you @goodmanmetrics ! https://t.co/pSSw3Ema7G
— Stelios (@SteliosSerghiou) January 27, 2019
Targeting Ras, the nemesis of cancer drug discovery. A new paper by my colleagues @BayerPharma is showcasing the beauty of lead design: Hybridizing a hit from a fragment screen with a HTS lead series gives the potent probe BAY-293: @EvotecAG @PNASNews https://t.co/wCBuMIn7zB pic.twitter.com/MT585n4lat
— Ingo Hartung (@HartungIngo) January 26, 2019
Another new Review is online today: 'The beginning of the end for conventional RECIST — novel therapies require novel imaging approaches' by Moritz Wildgruber and colleagues - https://t.co/c1WqG4yoMN pic.twitter.com/l1yQEXeaXI
— NatureRevClinOncol (@NatRevClinOncol) February 5, 2019
New by me in @NatRevDrugDisc (open access) https://t.co/yq0XAmXKCi:
— Frank David • Pharmagellan (@Frank_S_David) February 10, 2019
Does the stock market reward drug cos for getting breakthrough therapy designation? (TL;DR: not much & only briefly).
Thx to fab co-authors @DavidBiotech23 of @IMBA_Vienna & Shane Vandalsem of @washburnlaw. pic.twitter.com/2zdlpIhkXY
Human alpha and gamma pancreatic cells can be reprogrammed to produce insulin, reports a paper in Nature. Typically, only pancreatic beta cells produce insulin. The modified cells can also relieve the symptoms of diabetes when transplanted into mice. https://t.co/RfRBuBhPNS pic.twitter.com/niiNvDWxYk
— nature (@nature) February 14, 2019